Oral fluoroquinolones are associated with a small but significantly increased risk of acute kidney injury (AKI), Steven T. Bird, PharmD, MS, of the FDA, and colleagues reported online ahead of print in the Canadian Medical Association Journal.
In a study of 1,292 men with AKI and 12,651 matched controls, current use of fluoroquinolones—particularly ciprofloxacin and moxifloxacin—was associated with a twofold increased risk of AKI compared with no use.
n addition, concomitant use of an oral fluoroquinolone and a renin-angiotensin-system blocker increased the risk of acute renal failure by 4.5-fold.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.